• Kamran Saeed Radiation oncology department, SKMCH&RC, Lahore
  • Tabinda Sadaf Radaition Oncology, SKMCH&RC, Lahore
  • Aamir A Syed Surgical omcology department, SKMCH&RC, Lahrore
  • Neelam Siddique Medical Oncology department, SKMCH&RC, Lahore
  • Arif Jamshed Radiation oncology department, SKMCH&RC, Lahore


Objectives: Malignant ovarian germ cell tumours (MOGCTs) are rare, but aggressive tumours seen mostly in young women or adolescent girls. The aim of our study was to evaluate the survival outcomes of MOGCT patients treated at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.

Materials and Methods: One hundred and nine females were retrospectively identi ed through hospital information system with MOGCT from 2007 to 2013. Histology was based on the WHO classi cation. Tumours were staged according to the Federation of Gynaecology and Obstetrics staging system. Overall survival (OS) and disease-free survival (DFS) were determined by the Kaplan–Meier method. All patients were included in the study. Patient who had been lost to follow-up was contacted through telephone.

Results: Mean presenting age was 20 years (range 4–54). 38% of patients had Stage I, 7% had Stage II, 25% had Stage III and 30% of patients had Stage IV disease. Based on histology, 42% had dysgerminoma, 25% had mixed germ cell tumours, 18% had yolk sac tumour, 13% had teratoma and 2% had embryonal carcinoma. Median follow-up time was 41 months. All patients underwent initial surgery, of which 86 (79%) had fertility-preserving surgery. 91 (84%) patients received adjuvant chemotherapy and 18 (16%) were kept on surveillance. The chemotherapy regimen used was a combination of bleomycin, etoposide and cisplatin. 89 patients had a complete remission, 14 had partial response and one had progressive disease. Five patients had relapsed disease, four distant and one local. The 5 year OS was 91% and DFS was 88%.

Conclusion: MOGCTs have a good prognosis. Fertility-sparing surgery was possible in the majority of cases. BEP regimen has excellent activity and acceptable toxicity in patients with MOGCT.

Key words: Disease-free survival, malignant ovarian germ cell tumours, overall survival 


Bhurgri Y, Shaheen Y, Kayani N, et al. Incidence, trends and morphology of ovarian cancer in Karachi (1995-2002). Asian Pac J Cancer Prev 2011;12:1567-71.

Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev 2008;34:427-41.

Chan JK, Tewari KS, Waller S, et al. The in uence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol 2008;98:111-6.

Sviracević B, Sedlar S, Malobabić D, et al. Mixed malignant germ cell tumor of ovary. Med Pregl 2011;64:93-5.

Bilici A, Inanc M, Ulas A, et al. Clinical and pathologic features of patients with rare ovarian tumors: Multi-center review of 167 patients by the anatolian society of medical oncology. Asian Pac J Cancer Prev 2014;14:6493-9.

Parkinson CA, Hatcher HM, Ajithkumar TV. Management of malignant ovarian germ cell tumors. Obstet Gynecol Surv 2011;66:507-14.

Gershenson DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol 2012;55:65-74.

Low JJ, Ilancheran A, Ng JS. Malignant ovarian germ- cell tumours. Best Pract Res Clin Obstet Gynaecol 2012;26:347-55.

Solheim O, Kærn J, Tropé CG, et al. Malignant ovarian germ cell tumors: Presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). Gynecol Oncol 2013;131:330-5.

Matei D, Brown J, Frazier L. Updates in the management of ovarian germ cell tumors. Am Soc Clin Oncol Educ Book 2013;2013:210-6.

Mahdi H, Swensen RE, Hanna R, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ

cell tumour of the ovary. Br J Cancer 2011;105:493-7.

Vazquez I, Rustin GJ. Current controversies in the management of germ cell ovarian tumours. Curr Opin Oncol 2013;25:539-45.

Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumours of the ovary in children and adolescents: An intergroup study. J Pediatr Surg 2004;39:424-9.

Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second- line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005;23:6549-55.

Lee KH, Lee IH, Kim BG, et al. Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: A Korean gynecologic oncology group study. Int J Gynecol Cancer 2009;19:84-7.

Alcazar JL, Guerriero S, Pascual MA, et al. Clinical and sonographic features of uncommon primary ovarian malignancies. J Clin Ultrasound 2012;40:323-9.

Shen K. Problems of fertility preservation treatment in gynecologic oncology. Zhonghua Fu Chan Ke Za Zhi 2006;41:219 21.

Abdel-Hady ES, Abdel-Hady Hemida R, Gamal A, et al. Fertility sparing surgery for ovarian tumors in children and young adults. Arch Gynecol Obstet 2012;285:469-71.

Matsushita H, Arai K, Fukase M, et al. Growing teratoma syndrome of the ovary after fertility-sparing surgery and successful pregnancy. Gynecol Obstet Invest 2010;69:221-3.

How to Cite
Saeed K, Sadaf T, Syed AA, Siddique N, Jamshed A. MALIGNANT OVARIAN GERM CELL TUMOURS (MOGCT); SURVIVAL OUTCOMES FROM A SINGLE INSTITUTION IN PAKISTAN. J Cancer Allied Spec [Internet]. 2015Nov.1 [cited 2021Sep.27];1(2). Available from:
Original Research Article